ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M

ANI PHARMACEUTICALS INC

Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.
No further royalty due from January 1, 2025 forward; buyout covers all future net revenues.
Funded with cash on hand; enhances financial flexibility for Retina portfolio growth.
CEO Nikhil Lalwani states the transaction reflects commitment to maximizing long-term value of ILUVIEN and YUTIQ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.